CAR T therapy holds unprecedented promise for not just the treatment but the curing of cancer; however, barriers include complex procedures, high cost of implementation and manufacturing, and the application to solid tumors. Accordingly, many developments are ongoing to improve CAR activities as well as their generation. In vivo gene delivery to T cells holds promise as a therapeutic platform to treat various diseases by a simpler and less expensive means. The generation of chimeric antigen receptor (CAR) T cells in vivo can be achieved by delivering mRNA in T cell-targeted lipid nanoparticles (LNPs) and in vivo programming. This novel track at PEGS Europe will review innovative CAR structures, gene-editing tools, and gene delivery techniques applied in immunotherapy to help design and develop new CAR constructs and engineer in vivo therapies. Various approaches and technologies will be assessed for their immunogenicity, potency, and modes of CAR delivery, both permanent and transient. This conference will examine what it will take to transform new CAR constructs and in vivo CAR therapy from proof-of-concept to a robust technology for clinical use.
Scientific Advisory Board:
Christian J. Buchholz, PhD, Professor & Head, Molecular Biotechnology & Gene Therapy, Paul Ehrlich Institut
Ulf Grawunder, CEO, T-CURX
Astero Klampatsa, PhD, Team Leader, Thoracic Oncology Immunotherapy Group, Institute of Cancer Research (ICR)